Description
M-CENK is an experimental therapy currently being studied in clinical trials for various cancers, including colorectal cancer. It is a type of immunotherapy that uses a patient's own immune cells (specifically, Mononuclear Cells or MNCs) to potentially help the body fight cancer. The process involves collecting these cells from the patient (apheresis), modifying them in a lab, and then infusing them back into the patient. In the trials for colorectal cancer, M-CENK is being tested in combination with another investigational drug called N-803. The trials are in early phases (Phase 1), meaning they are primarily focused on determining the safety and feasibility of the treatment, as well as looking for early signs of effectiveness. The trials often enroll patients who have not responded well to standard treatments. The specific eligibility criteria for these trials may include factors like PD-L1 expression levels in the tumor.
Mechanism of Action
M-CENK is an autologous cellular immunotherapy. This means that immune cells (Mononuclear Cells or MNCs) are collected from the patient's own blood. These cells are then processed or modified in a laboratory setting. The specific modifications or activation processes applied to the MNCs to enhance their anti-tumor activity are being investigated. The goal is to create M-CENK cells that can recognize and attack cancer cells when infused back into the patient. It is often given in combination with N-803, another investigational agent, and the exact mechanism of action of the combination is under study.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.